Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)

Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease, with a median survival of 2–3 years and variable natural history, characterized by gradual and progressive deterioration. Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication, associated...

Full description

Bibliographic Details
Main Authors: Jean-Marc Naccache, Melissa Montil, Jacques Cadranel, Marine Cachanado, Vincent Cottin, Bruno Crestani, Dominique Valeyre, Benoit Wallaert, Tabassome Simon, Hilario Nunes
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Pulmonary Medicine
Subjects:
Idiopathic pulmonary fibrosis
Acute exacerbation
Cyclophosphamide
Online Access:http://link.springer.com/article/10.1186/s12890-019-0830-x

Internet

http://link.springer.com/article/10.1186/s12890-019-0830-x

Similar Items